SG11201408196RA - Designed ankyrin repeat proteins binding to platelet-derived growth factor - Google Patents

Designed ankyrin repeat proteins binding to platelet-derived growth factor

Info

Publication number
SG11201408196RA
SG11201408196RA SG11201408196RA SG11201408196RA SG11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA
Authority
SG
Singapore
Prior art keywords
platelet
growth factor
derived growth
ankyrin repeat
repeat proteins
Prior art date
Application number
SG11201408196RA
Inventor
Michael Baumann
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of SG11201408196RA publication Critical patent/SG11201408196RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/49Platelet-derived growth factor [PDGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201408196RA 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor SG11201408196RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12174020 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (1)

Publication Number Publication Date
SG11201408196RA true SG11201408196RA (en) 2015-03-30

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408196RA SG11201408196RA (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Country Status (16)

Country Link
US (2) US9163070B2 (en)
EP (1) EP2867360B1 (en)
JP (1) JP2015522576A (en)
KR (1) KR20150023957A (en)
CN (1) CN104508129A (en)
AU (1) AU2013283296A1 (en)
BR (1) BR112014032316A2 (en)
CA (1) CA2877584A1 (en)
HK (1) HK1209156A1 (en)
IL (1) IL236428A0 (en)
IN (1) IN2014MN02522A (en)
MX (1) MX2014015825A (en)
RU (1) RU2014150224A (en)
SG (1) SG11201408196RA (en)
WO (1) WO2014001442A1 (en)
ZA (1) ZA201408872B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
KR20140032356A (en) 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 Improved n-terminal capping modules for designed ankyrin repeat protein
HUE046134T2 (en) 2012-05-07 2020-02-28 Allergan Inc Method of treating amd in patients refractory to anti-vegf therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (en) 2013-05-31 2021-07-27 分子组合公司 Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2016005969A1 (en) 2014-07-07 2016-01-14 Yeda Research And Development Co. Ltd. Method of computational protein design
US20170226158A1 (en) * 2014-08-11 2017-08-10 Medimmune Limited Intracellular antigen binding
CN107148429B (en) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 anti-PDGF-B antibodies and methods of use
EP3218399A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use in ophthalmology
KR20170082594A (en) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 Anti-ang2 antibodies and methods of use
BR112017009817A2 (en) 2014-11-10 2018-02-14 Hoffmann La Roche anti-il-1beta antibodies and methods of use
EP4272838A3 (en) 2015-04-02 2024-01-10 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
WO2018054971A1 (en) 2016-09-22 2018-03-29 Molecular Partners Ag Recombinant binding proteins and their use
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
US11127483B2 (en) 2017-03-07 2021-09-21 Igc Bio, Inc. Computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
EP3768833A1 (en) 2018-03-22 2021-01-27 Charité - Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
WO2019238966A1 (en) 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
CA3113306A1 (en) 2018-10-08 2020-04-16 Universitat Zurich Her2-binding tetrameric polypeptides
WO2020104627A1 (en) 2018-11-21 2020-05-28 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
EP3908274A1 (en) 2019-01-11 2021-11-17 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2020207771A1 (en) 2019-04-10 2020-10-15 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
SG11202112921VA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Multispecific proteins
WO2020245175A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
MX2021014601A (en) 2019-06-04 2022-02-11 Molecular Partners Ag RECOMBINANT PROTEINS OF BINDING TO FAP AND THEIR USE.
US20220332845A1 (en) 2019-09-05 2022-10-20 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
WO2021116469A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
US20230151118A1 (en) 2020-04-06 2023-05-18 Universität Zürich Artc1 ligands for cancer treatment
CA3176845A1 (en) 2020-05-06 2021-11-11 Patrick AMSTUTZ Novel ankyrin repeat binding proteins and their uses
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
KR20230048151A (en) 2020-08-18 2023-04-10 유니버시타트 취리히 CD25 biased anti-IL-2 antibody
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
WO2022171831A1 (en) 2021-02-11 2022-08-18 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
US20240150475A1 (en) 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024509904A (en) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト A novel DARPin-based multispecific T cell engager
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
US20240156980A1 (en) 2021-03-09 2024-05-16 Molecular Partners Ag Protease cleavable prodrugs
WO2023012350A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
AU2022324711A1 (en) 2021-08-05 2024-02-01 Immunos Therapeutics Ag A modified hla-b57 with increased expression levels
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
CN118354784A (en) 2021-12-14 2024-07-16 分子合作伙伴股份公司 Designed repeat domains with dual binding specificity and uses thereof
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
AU2023317655A1 (en) 2022-08-01 2025-01-23 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024133013A1 (en) 2022-12-19 2024-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. Means and methods to target endogenous condensates
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (en) 1997-04-23 2006-12-07 Universität Zürich METHOD OF DETECTING NUCLEIC ACID MOLECULES COPYING FOR (POLY) PEPTIDES THAT INTERACT WITH TARGET MOLECULES
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
EP2149604A1 (en) * 2000-09-08 2010-02-03 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2003025019A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
ES2388138T3 (en) * 2003-08-27 2012-10-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
CA2585435A1 (en) * 2004-11-12 2006-05-18 Bayer Schering Pharma Aktiengesellschaft Recombinant newcastle disease virus
WO2006129828A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
JP5042218B2 (en) 2005-07-08 2012-10-03 ユニバーシティ・オブ・チューリッヒ Phage display using translocation simultaneously with translation of the fusion polypeptide
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
ES2422007T3 (en) 2007-06-21 2013-09-06 Univ Muenchen Tech Biological active proteins that have increased stability in vivo and / or in vitro
ES2614284T3 (en) 2007-11-30 2017-05-30 Glaxo Group Limited Antigen binding constructs
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
WO2009115919A2 (en) * 2008-03-19 2009-09-24 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
ES2836948T3 (en) * 2008-11-03 2021-06-28 Molecular Partners Ag Binding proteins that inhibit VEGF-A receptor interaction
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
KR20140032356A (en) * 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 Improved n-terminal capping modules for designed ankyrin repeat protein
EA201391607A1 (en) * 2011-04-29 2014-04-30 Янссен Байотек, Инк. BINDING IL4 / IL13 PROTEINS WITH REPEATERS AND THEIR APPLICATION

Also Published As

Publication number Publication date
CA2877584A1 (en) 2014-01-03
US9163070B2 (en) 2015-10-20
WO2014001442A1 (en) 2014-01-03
MX2014015825A (en) 2015-08-10
CN104508129A (en) 2015-04-08
RU2014150224A (en) 2016-08-20
IL236428A0 (en) 2015-02-26
EP2867360B1 (en) 2019-05-08
ZA201408872B (en) 2016-05-25
KR20150023957A (en) 2015-03-05
JP2015522576A (en) 2015-08-06
AU2013283296A1 (en) 2015-02-05
HK1209156A1 (en) 2016-03-24
US20140005125A1 (en) 2014-01-02
IN2014MN02522A (en) 2015-07-17
US20150368302A1 (en) 2015-12-24
EP2867360A1 (en) 2015-05-06
BR112014032316A2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
IL236428A0 (en) Designed ankyrin repeat proteins binding to platelet- derived growth factor
IL240838A0 (en) Anti-lag-3 binding proteins
SG10201607962RA (en) Artificial nucleic acid molecules
IL235128A0 (en) Nucleic acid sample preparation
ZA201504023B (en) Bcma antigen binding proteins
AP2015008266A0 (en) 1L-18 binding molecules
IL222323A0 (en) Tnf - alpha binding proteins
EP2932375A4 (en) Matching opportunity to context
ZA201404481B (en) Il-1 binding proteins
ZA201500203B (en) Transposition-mediated identification of specific binding or functional proteins
SG11201504249XA (en) Methods to control protein heterogeneity
PL2914287T3 (en) Binding members to il-1 beta
IL235134A0 (en) Il-6 binding molecules
EP2911694A4 (en) Anti-infective binding proteins that bind aip2
PL2851083T3 (en) Radiation-sterilization-resistant protein composition
EP2999710A4 (en) Peptides binding to parallel-stranded g-quadruplexes
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
GB201200563D0 (en) Binding molecule
SG11201503862XA (en) Biotinylated protein
GB201213672D0 (en) Protein
GB201211286D0 (en) Novel biological factor
GB201215901D0 (en) Protein modification
GB201214293D0 (en) Binding surfaces
GB201202569D0 (en) Compositions for binding to amyloid proteins
GB201214501D0 (en) Protein bites